Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer
This study has been completed.
Study NCT00148070   Information provided by University of Michigan Cancer Center

First Received on September 2, 2005.   Last Updated on October 3, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Metastatic Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
Docetaxel
Erythromycin Breath Test (ERMBT)
Additional drug interventions recognized in this trial
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Synthesis Inhibitors
Therapeutic Uses
Sponsors listed in this trial
University of Michigan Cancer Center
Aventis Pharmaceuticals
Rhone-Poulenc Rorer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services